Background: Long non-coding RNA (lncRNA) with little or no coding ability has shown a variety
of biological functions in cancer, including epigenetic regulation, DNA damage, regulation of microRNAs, and
participation in signal transduction pathways. LncRNA can be used as an oncogene and tumor suppressor gene
through transcriptional regulation in cancer. For example, the over-expressed lncRNA DLEU2 promotes the occurrence
of laryngeal cancer, lung cancer, hepatocellular carcinoma, etc., and inhibits the progression of chronic
lymphocytic leukemia. Deleted in Lymphocytic Leukemia 2 (DLEU2), as one of the long non-coding RNAs,
was first found in chronic lymphoblastic leukemia and drawn into the progress of innumerable cancers. The
molecular mechanism of DLEU2 in multiple tumors will be revealed.
Methods: In this review, current studies on the biological functions and mechanisms of DLEU2 in tumors are
summarized and analyzed; related researches are systematically retrieved and collected through PubMed.
Results: DLEU2, a novel cancer-related lncRNA, has been demonstrated to be abnormally expressed in various
malignant tumors, including leukemia, esophageal cancer, lung cancer, glioma, hepatocellular carcinoma, malignant
pleural mesothelioma, bladder cancer, pancreatic cancer, pharynx and throat cancer, renal clear cell carcinoma,
breast cancer, osteosarcoma. Besides, lncRNA DLEU2 has been shown to be involved in the process of
proliferation, migration, invasion and inhibition of apoptosis of cancer cells.
Conclusion: Due to the biological functions and mechanisms involved in DLEU2, it may represent an available
biomarker or potential therapeutic target in a variety of malignant tumors.